South African health regulators—the South African Health Products Regulatory Authority (SAHPRA), the South African Pharmacy Council (SAPC), and the Health Professions Council of South Africa (HPCSA)—have issued a stern warning to medical professionals: continuing to prescribe, dispense, or stock recalled iDEXIS weight-loss injections will result in formal disciplinary action. The products, which include various formulations of semaglutide and tirzepatide, were classified as a Class I, Type A recall in June due to critical safety concerns and regulatory breaches.
Regulatory Enforcement and Professional Consequences
Regulators are moving beyond simple warnings, signaling that they intend to hold individual practitioners accountable. According to the joint statement released by the three bodies, any healthcare professional found to be in possession of, or actively prescribing, the recalled iDEXIS products risks formal disciplinary proceedings under the Medicines and Related Substances Act, 101 of 1965.
SAPC Registrar and CEO Vincent Tlala emphasized the severity of these sanctions, noting that pharmacists and pharmacy support personnel could face the removal of their names from the professional register. The regulators argue that because the products were recalled due to significant safety risks, any practitioner continuing to supply them is “knowingly” endangering public health.
A Class I, Type A recall is the most serious category of medicine recall issued by SAHPRA.
Findings from the iDEXIS Inspection
The regulatory crackdown follows a joint inspection conducted in May at the premises of iDEXIS (Pty) Ltd, which trades as Sentra Pharmacy in Silverton, Pretoria. SAHPRA and the SAPC uncovered several “critical regulatory breaches” during the site visit.
Key findings reported by the regulators include:
- Illegal Sourcing: The unauthorized importation of active pharmaceutical ingredients (APIs).
- Lack of Quality Control: An absence of testing to verify the potency, purity, and identity of the finished products.
- Manufacturing Risks: Inadequate sterile conditions, which regulators warned created an elevated risk of contamination.
- Pharmacovigilance Failures: The company lacked a system to monitor and report adverse drug reactions, despite reports of patients being hospitalized after using the products.
The Legal Dispute Over Compounded Medicines
While regulators maintain that the products pose a direct threat to public safety, iDEXIS has contested the findings. The company asserts that its compounding processes are fully compliant with the Medicines and Related Substances Act and the relevant Good Pharmacy Practice Guidelines.
iDEXIS maintains that its APIs are sourced from internationally approved manufacturers and have been independently tested. The company claims that over 200,000 patients have utilized its compounded medicines without reported adverse reactions. However, the Gauteng High Court in Pretoria ruled in June that iDEXIS had been manufacturing large quantities of injections using an unregistered form of semaglutide. The court clarified that only registered APIs may be used when compounding medicine for specific patients on an individual prescription basis.
Future Trends in GLP-1 Regulation
The global surge in demand for drugs like Ozempic, Wegovy, and Mounjaro has outstripped supply, creating a vacuum often filled by compounded alternatives.
Pro Tip: Patients currently using weight-loss injections should verify the registration status of their medication via the official SAHPRA website to ensure their batch is not part of an active recall.
Frequently Asked Questions
Why were the iDEXIS products recalled?
SAHPRA issued a Class I, Type A recall due to critical regulatory breaches, including illegal importation of ingredients, lack of product testing, and inadequate sterile manufacturing conditions.
Can a pharmacist still dispense these products?
No. The SAPC and SAHPRA have explicitly warned that any pharmacist or medical practitioner found dispensing or stocking these recalled products will face formal disciplinary action and potential removal from the professional register.
How can I check if my medication is safe?
Patients are directed to consult the official SAHPRA recall notice, which provides a comprehensive list of all affected batches. If you have concerns, contact your prescribing doctor immediately.
Have you been affected by medication recalls? Share your thoughts or questions in the comments below, and subscribe to our newsletter for the latest updates on health policy and regulatory changes.